Evidence map›Paper›PMID 41877892›Full record

ArticleClinical kidney journal2026

F18-FDG PET-CT in immune checkpoint inhibitor-associated acute interstitial nephritis: what is the diagnostic value?

Rafaella Maria da Cunha Lyrio, Victor D Cuenca Narvaez, Coraima Claudia Nava Chavez, Omar Al Refai, Michael Bold, Nelson Leung, Sandra M Herrmann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rafaella Maria da Cunha LyrioDepartment of Internal Medicine, Washington University, St. Louis, MO 63110, USA.
Victor D Cuenca NarvaezDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA.
Coraima Claudia Nava ChavezDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA.ORCID https://orcid.org/0000-0003-2663-7301
Omar Al RefaiDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA.
Michael BoldDepartment of Nuclear Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Nelson LeungDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA.ORCID https://orcid.org/0000-0002-5651-1411
Sandra M HerrmannDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA.ORCID https://orcid.org/0000-0002-3700-4537

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Immune checkpoint inhibitor-associated acute interstitial nephritis (ICI-AIN) requires a kidney biopsy for a definitive diagnosis. A recent study suggested that 2-deoxy-2-[18F] fluoro-D-glucose positron emission tomography-computed tomography (F Methods: This retrospective cohort study comprises 105 patients on ICI therapy who underwent F Results: Thirty-two patients were included (5 ICI-AIN, 7 AKI from other causes, 20 controls). Renal SUVs did not differ significantly among groups. In patients with serial PET-CTs, kidney SUVs tended to increase from baseline to AKI in ICI-AIN, but these changes were not statistically significant. Conclusions: In this biopsy-validated cohort, PET-CTs did not reliably distinguish ICI-AIN from other causes of AKI in patients receiving ICI therapy. Larger prospective studies are needed to validate these findings.

Indexed as

acute interstitial nephritisacute kidney injuryFDG PET–CTimmune checkpoint inhibitorsimmune-related adverse events

Identifiers

PMID41877892
PMCPMC13006872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.